Functional Dyspepsia Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Functional Dyspepsia Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

February 15
19:48 2023
Functional Dyspepsia Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Functional Dyspepsia pipeline constitutes 4+ key companies continuously working towards developing 4+ Functional Dyspepsia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Functional Dyspepsia pipeline constitutes 4+ key companies continuously working towards developing 4+ Functional Dyspepsia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.  

Functional Dyspepsia Overview

Functional Dyspepsia (FD) is a term for recurring signs and symptoms of indigestion that have no obvious cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. The etiology of functional dyspepsia is likely heterogeneous and multifactorial; however, the exact cause is not clearly understood.

 

Functional Dyspepsia Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Functional Dyspepsia Market.

 

The Functional Dyspepsia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Functional Dyspepsia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Functional Dyspepsia treatment therapies with a considerable amount of success over the years. Functional Dyspepsia Key players such as – Zeria Pharmaceutical, Tsumura and Company, and others, are developing therapies for the Functional Dyspepsia treatment 
  • Functional Dyspepsia Emerging therapies such as – Acofide, Rikkunshito, and others are expected to have a significant impact on the Functional Dyspepsia market in the coming years.   
  • In 2021, the US Food and Drug Administration (FDA) approved GastroPlus, a non-prescription dietary supplement containing alpha-galactosidase, an enzyme that helps break down complex carbohydrates that can contribute to bloating and gas.

 

Route of Administration

Functional Dyspepsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

 

Functional Dyspepsia Pipeline Therapeutics Assessment

  • Functional Dyspepsia Assessment by Product Type
  • Functional Dyspepsia By Stage and Product Type
  • Functional Dyspepsia Assessment by Route of Administration
  • Functional Dyspepsia By Stage and Route of Administration
  • Functional Dyspepsia Assessment by Molecule Type
  • Functional Dyspepsia by Stage and Molecule Type

 

DelveInsight’s Functional Dyspepsia Report covers around 4+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Functional Dyspepsia Therapeutics Market include:

Key companies developing therapies for  Functional Dyspepsia treatment are – RaQualia Pharma Inc, Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, Renexxion LLC, Zeria Pharmaceutical Co Ltd., and others

 

Emerging Functional Dyspepsia Drugs Under Different Phases of Clinical Development Include:

  • Acofide: Zeria Pharmaceutical
  • Rikkunshito: Tsumura and Company, Tokyo, Japan

 

Get a Free Sample PDF Report to know more about Functional Dyspepsia Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/functional-dyspepsia-pipeline-insight

 

Functional Dyspepsia Pipeline Analysis:

The Functional Dyspepsia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Functional Dyspepsia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Functional Dyspepsia Treatment.
  • Functional Dyspepsia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Functional Dyspepsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Functional Dyspepsia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Functional Dyspepsia product details are provided in the report. Download the Functional Dyspepsia pipeline report to learn more about the emerging Functional Dyspepsia therapies

 

Scope of Functional Dyspepsia Pipeline Drug Insight    

  • Coverage: Global
  • Key Functional Dyspepsia Companies: Zeria Pharmaceutical, Tsumura and Company, and others
  • Key Functional Dyspepsia Therapies: Acofide, Rikkunshito, and others
  • Functional Dyspepsia Therapeutic Assessment: Functional Dyspepsia current marketed and Functional Dyspepsia emerging therapies
  • Functional Dyspepsia Market Dynamics: Functional Dyspepsia market drivers and Functional Dyspepsia market barriers 

 

Request for Sample PDF Report for Functional Dyspepsia Pipeline Assessment and clinical trials

 

Table of Contents

1

Functional Dyspepsia Report Introduction

2

Functional Dyspepsia Executive Summary

3

Functional Dyspepsia Overview

4

Functional Dyspepsia- Analytical Perspective In-depth Commercial Assessment

5

Functional Dyspepsia Pipeline Therapeutics

6

Functional Dyspepsia Late Stage Products (Phase II/III)

7

Functional Dyspepsia Mid Stage Products (Phase II)

8

Functional Dyspepsia Early Stage Products (Phase I)

9

Functional Dyspepsia Preclinical Stage Products

10

Functional Dyspepsia Therapeutics Assessment

11

Functional Dyspepsia Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Functional Dyspepsia Key Companies

14

Functional Dyspepsia Key Products

15

Functional Dyspepsia Unmet Needs

16 

Functional Dyspepsia Market Drivers and Barriers

17

Functional Dyspepsia Future Perspectives and Conclusion

18

Functional Dyspepsia Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Functional Dyspepsia drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

Related Articles

Categories